2024-02-11 02:41:56 ET
Summary
- Pre-PDUFA positioning is a good opportunity to buy ImmunityBio stock at a low price.
- Multiple catalysts could drive the stock price higher over the next 24 months.
- ImmunityBio has the potential to become a big pharma company rather than being sold.
Editor's note: Seeking Alpha is proud to welcome Ben Rogers as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Premium. Click here to find out more » ...
Read the full article on Seeking Alpha
For further details see:
ImmunityBio: Buy Low Now Vs. Buy High Later